OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company headquartered in Miami, Florida, United States. Incorporated in 1991, with its current platform established in 2007, the company focuses on delivering next-generation solutions for serious diseases across established global markets. Its mission is dedicated to advancing proven technologies to transform patients' lives by addressing unmet medical needs.

The company operates through two primary segments: diagnostics and pharmaceuticals. Its diagnostics division includes BioReference Health, which provides clinical laboratory testing services, and specialty diagnostic products such as the 4Kscore test for prostate cancer. In pharmaceuticals, OPKO Health offers products like Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in chronic kidney disease patients, and has an economic interest in NGENLA, a once-weekly human growth hormone therapy partnered with Pfizer. Additionally, its research and development efforts, primarily through its wholly-owned subsidiary ModeX Therapeutics, are focused on advancing multispecific therapies for cancer and infectious diseases.

Dr. Phillip Frost has served as the CEO and Chairman of OPKO Health, Inc. since March 2007. Recent developments include the presentation of preclinical data for OPKO Biologics' OPK8801001 in Acromegaly at ENDO 2026 in June 2026, and ModeX Therapeutics presenting data on CAR-T cell generation in May 2026. The company also expanded its Nicoya Agreement for RAYALDEE® commercialization in Greater China and launched BioReference Direct™ for consumer-initiated diagnostic testing in May 2026. OPKO Health maintains a diversified market position, combining a national diagnostic platform with a portfolio of specialty pharmaceuticals and early-stage research assets, with operations spanning the U.S., Europe, Israel, and Latin America.